Managing Director & Partner
Troy Mullane is a core member of the Health Care and Marketing, Sales & Pricing practices. He is a North America leader for biopharma launch and customer model.
Since joining BCG in 2011, Troy has worked with a variety of clients in the health care space, especially in biopharma where his clients range from pre-commercial biotechs to top-ten biopharma manufacturers. He has particular expertise in brand strategy; customer model design; and value, access, and pricing.
Troy’s support for biopharma clients covers strategy from product launch through commercialization and life-cycle management, across multiple disease categories including oncology, hematology, neuroscience, cardiovascular, inflammation/immunology, rare disease, and allergy. This experience also covers a range of therapeutic modalities, including small molecule, innovative biologics, biosimilars, and cell and gene therapies.
Prior to joining BCG, Troy worked for General Electric in internal audit. He also spent six months in 2018 seconded to a biotech, leading launch planning for their first commercial asset.
To advance from promise to value, biopharma companies need to articulate and execute a bold vision for analytics as a fully scaled, continuously applied internal capability.